|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.7.7.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B:
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chains A, B:
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chains A, B:
E.C.3.1.-.-
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
Chains A, B:
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
Chains A, B:
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 7:
|
 |
Chains A, B:
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Med Chem
44:1866-1882
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
|
|
J.H.Chan,
J.S.Hong,
R.N.Hunter,
G.F.Orr,
J.R.Cowan,
D.B.Sherman,
S.M.Sparks,
B.E.Reitter,
C.W.Andrews,
R.J.Hazen,
M.St Clair,
L.R.Boone,
R.G.Ferris,
K.L.Creech,
G.B.Roberts,
S.A.Short,
K.Weaver,
R.J.Ott,
J.Ren,
A.Hopkins,
D.I.Stuart,
D.K.Stammers.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
A series of 2-amino-5-arylthiobenzonitriles (1) was found to be active against
HIV-1. Structural modifications led to the sulfoxides (2) and sulfones (3). The
sulfoxides generally showed antiviral activity against HIV-1 similar to that of
1. The sulfones, however, were the most potent series of analogues, a number
having activity against HIV-1 in the nanomolar range. Structural-activity
relationship (SAR) studies suggested that a meta substituent, particularly a
meta methyl substituent, invariably increased antiviral activities. However,
optimal antiviral activities were manifested by compounds where both meta groups
in the arylsulfonyl moiety were substituted and one of the substituents was a
methyl group. Such a disubstitution led to compounds 3v, 3w, 3x, and 3y having
IC50 values against HIV-1 in the low nanomolar range. When gauged for their
broad-spectrum antiviral activity against key non-nucleoside reverse
transcriptase inhibitor (NNRTI) related mutants, all the di-meta-substituted
sulfones 3u-z and the 2-naphthyl analogue 3ee generally showed single-digit
nanomolar activity against the V106A and P236L strains and submicromolar to low
nanomolar activity against strains E138K, V108I, and Y188C. However, they showed
a lack of activity against the K103N and Y181C mutant viruses. The elucidation
of the X-ray crystal structure of the complex of 3v (739W94) in HIV-1 reverse
transcriptase showed an overlap in the binding domain when compared with the
complex of nevirapine in HIV-1 reverse transcriptase. The X-ray structure
allowed for the rationalization of SAR data and potencies of the compounds
against the mutants.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
R.Hu,
F.Barbault,
F.Maurel,
M.Delamar,
and
R.Zhang
(2010).
Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies.
|
| |
Chem Biol Drug Des,
76,
518-526.
|
 |
|
|
|
|
 |
B.Hemmateenejad,
R.Sabet,
and
A.Fassihi
(2009).
Quantitative structure-activity relationship studies on 2-amino-6-arylsulfonylbenzonitriles as human immunodeficiency viruses type 1 reverse transcriptase inhibitors using descriptors obtained from substituents and whole molecular structures.
|
| |
Chem Biol Drug Des,
74,
405-415.
|
 |
|
|
|
|
 |
J.D.Bauman,
K.Das,
W.C.Ho,
M.Baweja,
D.M.Himmel,
A.D.Clark,
D.A.Oren,
P.L.Boyer,
S.H.Hughes,
A.J.Shatkin,
and
E.Arnold
(2008).
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design.
|
| |
Nucleic Acids Res,
36,
5083-5092.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.Barreiro,
C.R.Guimarães,
I.Tubert-Brohman,
T.M.Lyons,
J.Tirado-Rives,
and
W.L.Jorgensen
(2007).
Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.
|
| |
J Chem Inf Model,
47,
2416-2428.
|
 |
|
|
|
|
 |
J.Ren,
C.E.Nichols,
A.Stamp,
P.P.Chamberlain,
R.Ferris,
K.L.Weaver,
S.A.Short,
and
D.K.Stammers
(2006).
Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
|
| |
FEBS J,
273,
3850-3860.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.P.Freitas
(2006).
MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners.
|
| |
Org Biomol Chem,
4,
1154-1159.
|
 |
|
|
|
|
 |
T.Maruyama,
S.Kozai,
Y.Demizu,
M.Witvrouw,
C.Pannecouque,
J.Balzarini,
R.Snoecks,
G.Andrei,
and
E.De Clercq
(2006).
Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil derivatives.
|
| |
Chem Pharm Bull (Tokyo),
54,
325-333.
|
 |
|
|
|
|
 |
B.M.Trost,
C.Pissot-Soldermann,
and
I.Chen
(2005).
A short and concise asymmetric synthesis of hamigeran B.
|
| |
Chemistry,
11,
951-959.
|
 |
|
|
|
|
 |
J.L.Medina-Franco,
A.Golbraikh,
S.Oloff,
R.Castillo,
and
A.Tropsha
(2005).
Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining.
|
| |
J Comput Aided Mol Des,
19,
229-242.
|
 |
|
|
|
|
 |
J.D.Pata,
W.G.Stirtan,
S.W.Goldstein,
and
T.A.Steitz
(2004).
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.
|
| |
Proc Natl Acad Sci U S A,
101,
10548-10553.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Barbany,
H.Gutiérrez-de-Terán,
F.Sanz,
and
J.Villà-Freixa
(2004).
Towards a MIP-based alignment and docking in computer-aided drug design.
|
| |
Proteins,
56,
585-594.
|
 |
|
|
|
|
 |
N.Sluis-Cremer,
N.A.Temiz,
and
I.Bahar
(2004).
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
|
| |
Curr HIV Res,
2,
323-332.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |